PMID-34288673 – Development of Cagrilintide Long-Acting Amylin Analogue
Lau DCW, Batterham RL, Garvey WT, Astrup A. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Clin Endocrinol Metab. 2021;106(11):e4799-e4801.
Quick Reference
| Property | Value |
|---|---|
| PMID | 34288673 |
| DOI | 10.1210/clinem/dgab529 |
| Year | 2021 |
| Journal | Journal of Clinical Endocrinology & Metabolism |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (review) |
| Peptide(s) Studied | Cagrilintide |
Key Findings
- Cagrilintide is an acylated, long-acting analog of human amylin designed for once-weekly subcutaneous dosing
- Amylin is co-secreted with insulin from pancreatic beta cells and acts on area postrema and hypothalamus
- Cagrilintide produces satiety via amylin receptor activation in the brainstem
- The acylation modification extends the half-life to approximately 7 days (vs 15 min for native amylin)
- Distinct mechanism from GLP-1 agonists: amylin pathway primarily affects meal size and gastric emptying
- Represents a novel therapeutic class for obesity treatment
Study Design
Brief review/editorial covering the pharmacological rationale, molecular design, and early clinical development of cagrilintide as a long-acting amylin analogue for obesity treatment.
Limitations
- Brief editorial/review format
- Limited depth compared to full review articles
- Published early in cagrilintide's clinical development
Clinical Relevance
Provides context for why amylin is a rational obesity target and how cagrilintide was engineered to overcome the limitations of native amylin (short half-life, fibrillation). The acylation strategy — similar to that used for semaglutide — enables once-weekly dosing. Understanding this mechanism is important for clinicians considering amylin-based therapies alongside GLP-1 agonists.
Related
#research #narrative-review #cagrilintide #evidence-level-V